Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/33768

Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real‑world observational study


no-thumbnailView/Open:

 Effectiveness of rituximab vs. ocrelizumab for the treatment.pdf



885,26 kB
Adobe PDF
Share:

This resource is restricted

Title:
Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real‑world observational study
Authors:
Alcalá, Carmen
Quintanilla-Bordás, Carlos  
Gascón, Francisco  
Perez-Sempere, Angel  
Navarro, Laura
Carcelén‑Gadea, María
Landete, Lamberto  
Mallada, Javier
Cañizares, Emmanuel
Belenguer, Antonio
Carratalá, Sara
Domínguez, José Andrés
Pérez‑Miralles, Francisco Carlos
Gil‑Perotín, Sara
Gasqué, Raquel
Cubas, Laura
Castillo, Jéssica
Casanova, Bonaventura  
Editor:
Springer
Department:
Departamentos de la UMH::Medicina Clínica
Issue Date:
2022
URI:
https://hdl.handle.net/11000/33768
Abstract:
Introduction Ocrelizumab, an antiCD-20 antibody, is the only drug approved to treat patients with primary progressive multiple sclerosis (pwPPMS). Not all candidates receive this treatment due to prescription limitations. Rituximab, another antiCD-20 antibody, has been used off-label in pwPPMS befo...  Ver más
Keywords/Subjects:
Esclerosis múltiple
ocrelizumab
Knowledge area:
CDU: Ciencias aplicadas: Medicina
Type of document:
info:eu-repo/semantics/article
Access rights:
info:eu-repo/semantics/closedAccess
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
DOI:
https://doi.org/10.1007/s00415-022-10989-0
Appears in Collections:
Artículos Medicina Clínica



Creative Commons ???jsp.display-item.text9???